What Is BioXcel Therapeutics, Inc. (BTAI) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, our multi-model framework produces a cautiously optimistic read on BioXcel Therapeutics, Inc. at $0.92. With an estimated intrinsic value of $1.05 and 3 of 5 models pointing higher, the average implied return is +14.1%. The most optimistic model, PWERM, places fair value at $2.47 (+167.6%), while Regime Cross — the most conservative — estimates $0.01 (-98.9%). This +266.5% gap reflects genuine analytical uncertainty about BioXcel Therapeutics, Inc.'s intrinsic worth.
What Do the Models Say About BTAI?
5 of 13 models are currently active for BTAI. Of these, 3 models suggest upside while 2 models suggest overvaluation. See which stocks rank higher →
How Does BTAI Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, BTAI ranks #224 by Quality of Company score. CirclFi's QOC score of 4.9/10 evaluates 32 fundamental signals. A score of 4.9 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
The Pharmaceutical Preparations sector introduces analytical considerations specific to pharmaceutical industry businesses. For BioXcel Therapeutics, Inc., metrics like revenue per drug provide important context that general-purpose valuation models may underweight.
Is BTAI a Value Trap?
CirclFi's Value Trap algorithm assigns BTAI a score of 30/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
5 of 13 models are active for BioXcel Therapeutics, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, BioXcel Therapeutics, Inc. scores 4.9 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +266.5% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every BTAI valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across BTAI's 5 active models, average confidence is 15%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad